KD Pharma expands CBD manufacturing capability with acquisition Fish oils supplier KD Pharma has moved more aggressively into the cannabinoid space with the acquisition of the manufacturing assets of a Swiss CBD and phyotextract specialist firm, the company announced today. The new development will be tightly focused on supply active pharmaceutical ingredients for new drug development, said Adam Ismail, chief strategy officer for the company. To some degree it’s a statement about how the uncertain regulatory framework for hemp/CBD nutritional products in the United States, Europe and elsewhere is inhibiting innovation. “Our focus is really on the pharma market for cannabinoids. That’s where we really see a lot of growth potential. It has a completely different regulatory framework from supplements,” Ismail told NutraIngredients-USA.